Patents by Inventor Catherine J. McMahan
Catherine J. McMahan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11939392Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.Type: GrantFiled: December 21, 2021Date of Patent: March 26, 2024Assignee: Aptevo Research and Development LLCInventors: Gabriela Hernandez-Hoyos, Elaine T. Sewell, Catherine J. McMahan, David Bienvenue, John W. Blankenship, Danielle Mitchell, Peter Pavlik
-
Publication number: 20230303720Abstract: Described herein are compositions comprising protein therapeutics, including multispecific polypeptides and fusion proteins, for intravenous administration. The compositions may comprise, for example, a multispecific protein, a buffer, an excipient, and a surfactant. In some embodiments, the compositions may comprise a multispecific protein, a succinate buffer, sucrose, and polysorbate 80. Also provided herein are clinical methods, including dosing regimens, for administration of the compositions to a subject in need thereof.Type: ApplicationFiled: January 13, 2021Publication date: September 28, 2023Inventors: Jonathan CLAPPER, David BIENVENUE, Scott STROMATT, Catherine J. MCMAHAN
-
Publication number: 20220363773Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.Type: ApplicationFiled: December 21, 2021Publication date: November 17, 2022Inventors: Gabriela HERNANDEZ-HOYOS, Elaine T. SEWELL, Catherine J. MCMAHAN, David BIENVENUE, John W. BLANKENSHIP, Danielle MITCHELL, Peter PAVLIK
-
Patent number: 11242400Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.Type: GrantFiled: September 21, 2017Date of Patent: February 8, 2022Assignee: Aptevo Research and Development LLCInventors: Gabriela Hernandez-Hoyos, Elaine T. Sewell, Catherine J. McMahan, David Bienvenue, John W. Blankenship, Danielle Mitchell, Peter Pavlik
-
Patent number: 10676533Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.Type: GrantFiled: March 22, 2018Date of Patent: June 9, 2020Assignee: Aptevo Research and Development LLCInventors: Gabriela Hernandez-Hoyos, Elaine T. Sewell, Catherine J. McMahan, David Bienvenue, John W. Blankenship, Danielle Mitchell, Peter Pavlik
-
Publication number: 20200165346Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.Type: ApplicationFiled: September 21, 2017Publication date: May 28, 2020Inventors: Gabriela Hernandez-Hoyos, Elaine T. Sewell, Catherine J. McMahan, David Bienvenue, John W. Blankenship, Danielle Mitchell, Peter Pavlik
-
Publication number: 20190071513Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.Type: ApplicationFiled: March 22, 2018Publication date: March 7, 2019Inventors: Gabriela Hernandez-Hoyos, Elaine T. Sewell, Catherine J. McMahan, David Bienvenue, John W. Blankenship, Danielle Mitchell, Peter Pavlik
-
Patent number: 10202452Abstract: The present invention relates to mono-specific and multi-specific polypeptides that specifically bind or interact with CD3. These polypeptides can be, but are not limited to, antibodies, fragments thereof, scFvs, Fabs, di-scFvs single domain antibodies, diabodies, dual variable domain binding proteins and polypeptides containing an antibody or antibody fragments. In one embodiment, a multi-specific polypeptide binds both a T-cell receptor complex on T-cells and a tumor antigen to induce target-dependent T-cell cytotoxicity, activation and proliferation.Type: GrantFiled: April 18, 2013Date of Patent: February 12, 2019Assignee: Aptevo Research and Development LLCInventors: Philip H Tan, Sateesh K Natarajan, Catherine J McMahan
-
Publication number: 20170008960Abstract: Single chain fusion proteins that specifically bind to a TCR complex or a component thereof, such as TCR?, TCR?, or CD3?, along with compositions and methods of use thereof are provided.Type: ApplicationFiled: February 10, 2016Publication date: January 12, 2017Inventors: Valerie Odegard, Catherine J. McMahan, Peter Robert Baum, Peter Armstrong Thompson, Philip Tan, John W. Blankenship, Sateesh Kumar Natarajan
-
Publication number: 20150232557Abstract: The present invention relates to mono-specific and multi-specific polypeptides that specifically bind or interact with CD3. These polypeptides can be, but are not limited to, antibodies, fragments thereof, scFvs, Fabs, di-scFvs single domain antibodies, diabodies, dual variable domain binding proteins and polypeptides containing an antibody or antibody fragments. In one embodiment, a multi-specific polypeptide binds both a T-cell receptor complex on T-cells and a tumor antigen to induce target-dependent T-cell cytotoxicity, activation and proliferation.Type: ApplicationFiled: April 18, 2013Publication date: August 20, 2015Inventors: Philip H Tan, Sateesh K Natarajan, Catherine J McMahan
-
Publication number: 20110217302Abstract: Single chain fusion proteins that specifically bind to a TCR complex or a component thereof, such as TCR?, TCR?, or CD3?, along with compositions and methods of use thereof are provided.Type: ApplicationFiled: October 9, 2009Publication date: September 8, 2011Applicant: Emergent Product Development Seattle, LLCInventors: Valerie Odegard, Catherine J. McMahan, Peter Robert Baum, Peter Armstrong Thompson, Philip Tan, John W. Blankenship, Sateesh Kumar Natarajan